EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection

Kazuto Tajiri iD, Yuka Hayashi, Aiko Murayama, Nozomu Muraishi, Masami Minemura, Ichiro Yasuda iD

Viruses · 2024

DOI: 10.3390/v17010044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Kazuto Tajiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Antiviral Agents, Guanine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achieving HBsAg seroclearance is a key goal in treating chronic hepatitis B virus (HBV) infection but remains difficult with nucleos(t)ide analogues (NAs). Tenofovir alafenamide fumarate (TAF), a recommended NA for managing chronic HBV infection (CHB), has uncertain effects on HBsAg levels and potential adverse events when used long-term after switching from entecavir (ETV). We retrospectively evaluated 77 CHB patients, including 47 who switched from ETV to TAF with a median follow-up of 40 months post-switch and a median of 60 months of HBsAg monitoring pre-switch. No significant change in HBsAg levels was observed in the overall cohort post-switch, consistent with the ETV continuation group. However, a significant decrease in HBsAg was noted in patients with HBsAg < 100 IU/mL at the time of switching. HBsAg loss occurred in three patients who switched to TAF. No adverse effects were observed, and TAF was well tolerated. The most significant factor associated with achieving HBsAg < 100 IU/mL was the Fib-4 index, a marker of liver fibrosis, at the time of switching. Switching from ETV to TAF is an effective strategy in CHB management, with hepatic inflammation potentially playing an essential role in achieving HBsAg decrease. Patients with increased Fib-4 index were significantly more likely to show decreased HBsAg. This finding suggests patients with mild to moderate fibrosis may respond better to TAF in terms of HBsAg reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B Surface AntigensAntiviral AgentsGuanineTenofovirAdenineHumansMaleFemaleMiddle AgedRetrospective StudiesAdultHepatitis B virusDrug SubstitutionAlanineAged

Stichwörter der Autor:innen

HBsAg decreasedyslipidemiahepatitis B virusnucleos(t)ide analogue switchingtenofovir alafenamide fumarate

Substanzen

entecavirHepatitis B Surface AntigensAntiviral AgentsGuaninetenofovir alafenamideTenofovirAlanineAdenine

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

ORCID-Profile: Kazuto Tajiri, Ichiro Yasuda

Förderung

  • Japan Society for the Promotion of Science
  • JSPS KAKENHI

Zitieren

APA

Tajiri, K., Hayashi, Y., Murayama, A., Muraishi, N., Minemura, M., & Yasuda, I. (2024). Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection. Viruses. https://doi.org/10.3390/v17010044

Vancouver

Tajiri K, Hayashi Y, Murayama A, Muraishi N, Minemura M, Yasuda I. Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection. Viruses. 2024. doi:10.3390/v17010044

BibTeX
@article{Tajiri2024,
  author = {Tajiri, Kazuto and Hayashi, Yuka and Murayama, Aiko and Muraishi, Nozomu and Minemura, Masami and Yasuda, Ichiro},
  title = {Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v17010044}
}
Kostenlos starten →